Which medications in the drug class Vasopressin Antagonists are used in the treatment of Polycystic Kidney Disease?

Updated: Mar 24, 2020
  • Author: Roser Torra, MD, PhD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Vasopressin Antagonists

The selective vasopressin V2-receptor antagonist, tolvaptan, causes an increase in urine water excretion that results in an increase in free water clearance (aquaresis), a decrease in urine osmolality, and a resulting increase in serum sodium concentration.

Tolvaptan (Jynarque)

Indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). This indication is specific for Jynarque (ie, not Samsca) as the dosing and duration differs. Because of the potential for serious liver injury, Jynarque is available only through a restricted distribution program.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!